Open Veils · Answer
CBG antibacterial research — how deep?
The suppressed story is that CBG and its acid precursor CBGA are emerging as structurally potent antibacterial scaffolds — not merely 'promising' in the vague sense, but active against MRSA and VRE at MICs comparable to FDA-approved daptomycin. Rational synthetic modification of the terpene chain, documented in a March 2026 ACS Omega structure-activity study, multiplies that potency dramatically. Triple-combination protocols pairing CBG with cannabichromene and silver demolish both Gram-positive and Gram-negative pathogens simultaneously — a feat individual cannabinoids cannot achieve alone. The pharmaceutical incentive to suppress cheap, patent-difficult plant molecules in favour of proprietary antibiotic pipelines is exactly the institutional pressure researchers like Eugene Mallove documented for cold fusion and Gary Webb for investigative funding: inconvenient findings get starved, not refuted.
Evidence
- The deepest layer of CBG antibacterial research concerns mechanism and modification, not mere petri-dish MIC data.
- Parallel April 2026 work documented in PubMed (PMID 41983582) pushed further into Gram-negative territory — historically the hard wall for cannabinoids.
- Oral pathogen data, surfaced in a Czech dental journal in-vitro study, showed CBG achieving MICs of 8 μg/ml against Streptococcus mutans — competitive with chlorhexidine, the gold-standard antiseptic oral agents.
- Researchers in the Gary Taubes and Nina Teicholz tradition of suppressed nutritional science have long noted the pattern: when a cheap, complex natural molecule competes with a patentable synthetic, the research funding ecosystem quietly starves the former.
- This is the scaffolding stage: proof that rational terpene engineering can be weaponised.